ORAL MEXILETINE IN HIGH-RISK PATIENTS AFTER MYOCARDIAL INFARCTION

Autor: D. Mcc. Boyle, Shanks Rg, D.E. Jewitt, D.G. Julian, R.W.F. Campbell, D. Chamberlain
Rok vydání: 1980
Předmět:
Zdroj: The Lancet. 316:1324-1327
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(80)92395-8
Popis: In a double-blind trial the antiarrhythmic effect of oral mexiletine (200-250 mg every 8 h) was investigated in 344 patients judged to be at high risk after acute myocardial infarction. The numbers of patients with ventricular ectopic complexes were similar in the mexiletine and placebo groups at each point of analysis. At 1 month fewer patients in the mexiletine group had couplets and multiform ventricular ectopic beats, but at 3 months the difference was not significant. The hourly average number of ventricular ectopic complexes was significantly reduced by mexiletine at both 1 month and 3 months. Potential unwanted effects of therapy, particularly those related to the central nervous system and the gastrointestinal tract, were more common in patients treated with mexiletine than in those on placebo. Side-effects led to 30 withdrawals in the mexiletine group and 6 in the placebo group. There was no evidence that mexiletine caused any important cardiovascular side-effects. 24 patients (13%) in the mexiletine group and 19 (12%) in the placebo group died. Thus mexiletine reduced the prevalence of ventricular arrhythmias in a high-risk group of patients with recent myocardial infarction, but no favourable effect on mortality was observed.
Databáze: OpenAIRE